Ochoa CF, Aguilar JL, Aragón TAR, Ayala JR, Carvajal GR, Cervantes SG, Cortés BR, Cortés EP, Criales CJL, Erazo VA, Fernández OA, Flores GA, Hernández TN, Hinojosa GJ, Jiménez RMÁ, Lázaro LM, León RE, Manzanilla GHA, Martínez CP, Moyaho I, Murphy SC, Pérez ZF, Serrano BE, Solano MHA, Solares SME, Torres SJ

Language: Spanish
References: 32
Page: 301-311
PDF size: 151.93 Kb.

ABSTRACT

The first two days of december 2006, a group of twenty five Mexican opinion leaders in Oncology, Urology, Surgery, Radiology, Internal Medicine and other specialities related to cancer treatment, gathered in Cuernavaca, Morelos, with the aim of developing a documented guideline on the treatment of renal cell carcinoma (RCC). Most of these specialists are currently working at leading positions in the most important third level hospitals in the country, and their opinion has paramount importance for getting a comprehensive, detailed and suited document that applies and resembles the national possibilities and impairing factors for the treatment of RCC in Mexico. This important disease is reaching new possibilities as an intention to cure treatment disease in many of the cases diagnosed timely, and that makes its whole approach more complex, interesting and promising. There are many new options for the clinical approach of RCC (for example, the inhibition of pathological molecular signalling with monoclonal antibodies and multikinase inhibitors), and getting them known by Mexican clinicians is the most important underlying reason and rationalfor this meeting, since presenting an updated and throughout guideline on the specific clinical approach of RCC will help clinicians and patients to reach better clinical results while taking care of quality of life.

REFERENCES

1. Jemal A, Siegel R et al. Cancer Statistics, 2006. CA. Cancer J Clin. 2006;56:106-130.

2. Sobin LH, Wittekind et al, International Union Against Cancer (UICC) TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss, 2002:193-195.

3. Registro Histopatológico de Neoplasias en México (RHPNM) 2000. Grupos etáreos, DGE/SSA.

4. Sene AP, Hunt L et al. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol. 1992;70(2):125-34.

5. De Vita VT, Jr. Hellman et al. Cancer Principles and Practice of Oncology. Sixth edition. Philadelphia, Pa; Lippincott Williams & Wilkins, 2001.

6. Jiménez Ríos MA, Solares Sánchez ME et al. Angiogénesis: Mecanismos moleculares y blancos terapéuticos. Revista del Instituto Nacional de Cancerología de México. Junio 2006;1(2):73-121.

7. Robert C Flanigan. Subspecialty certification in urology: a US prospective. Nature Clinical Practice Urology. (2006) 3, 509. doi:10.1038/ncpuro0607.

8. Mancuso A., Sternberg C. What’s new in the treatment of metastatic kidney cancer? BJU Int. 2005; 95:1171-80.

9. Panelli MC, E Wang E, Marincola FM. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res. 2005 May 15;11(10):3610-3.

10. National Comprehensive Cancer Network. Practice guidelines in oncology v.1.2007 Kidney Cancer.

11. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H; European Association of Urology. Guidelines on Renal Cell Cancer. Eur Urol. 2001;40:252-5.

12. B. Ljungberg, DC, Hanbury MA et al. Guidelines on Renal Cell Carcinoma. European Association of Neurology, 2006 (In Press).

13. Escudier B, Szczylik C, Eisen T et al, The 2006 ASCO meeting featured promising findings among tyrosine kinase inhibitors. (Abstract 4524.)

14. Ratain MJ, Eisen T et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-12.

15. Motzer RJ, Michaelson MD et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet derived growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.

16. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.

17. Motzer RJ, Hutson TE et al. Phase III randomized trial of sunitinib malate (SU11248) vs IFN as first line systemic treatment for patients with metastatic renal cell carcinoma. J Clin Oncol. 2006, 24(Suppl 1):2S. Abstract 3.

18. Patard J, Leclercq N, Fergelot P. Understanding the Importance of Smart Drugs in Renal Cell Carcinoma. Eur Urol. 2006;49:633-43.

19. Yang J, Haworth L, Sherry R et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34.

20. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336-47.

21. Jonasch E, Haluska F et al. Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. The Oncologist. 2001;6:34-55.

22. Gitlitz B, Figlin R et al. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin N Am. 2003; 30:589-600.

23. Bradley C, Leibovich, Michael L. Surgical Management of Renal Cell Carcinoma. Semin Oncol. 33:552- 62© Elsevier Inc ?AÑO?

24. Vaidya A, Ciancio G, Soloway M. Surgical Techniques for Treating a Renal Neoplasm Invading The Inferior Vena Cava. J Urol. 2003;169:435-444.

25. Hiroyuki Y, Dan T, Hiroshi I et al. Should the inferior vena cava be reconstructed after resection for malignant tumors? The American Journal of Surgery. 2005;189:419-424.

26. Yonover P, Flanigan R et al. Should radical nephrectomy be performed in the face of surgically incurable disease? Curr Op in Urol. 2000;10:429-434.

27. Wood Ch. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin N Am. 2003;30:581-588.

28. McLaughlin JK. Epidemiologic aspects of renal cell cancer. Sem Onc. 2000;27(2):115-123.

29. Becker G, Jeremic B, Korrmann R.D. and Bamberg M. Modern Management of Brain Metastases: Prognostic Factors in Radiosurgery. Front Radiat Ther Oncol, Basel Karger. 2000;34:130-144.

30. Huguenin PU. Radiotherapy for metastatic carcinomas of the kidney or melanomas: An analysis using palliative end points. Int J Radiation Oncology Biol Phys 1998;41(2):401-405.

31. Baumana G. Radiopharmaceuticals for the palliation of painful bone metastases-a systematic review. Radiotherapy and Oncology. 2005;75(3):258 E1-258 E13.

32. Zalla MJ, Roenigk RK: Metastatic carcinoma. In: Maloney M, Helm KF, eds. Surgical Dermatopathology. Malden, Mass: Blackwell, 1999:389-436.